[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCAb1E2ywHfXCM8_aVnrsTWnj84kM69_CnFk-IDR0SS0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":48,"rows":55},"Ramathibodi Hospital",[4],63,false,5,6,16325,7,37,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Vascular Calcification",3,{"name":18,"count":19},"Anterior Cruciate Ligament Injuries",2,{"name":21,"count":19},"Lumbar Disc Herniation",{"name":23,"count":19},"Osteoarthritis, Knee",{"name":25,"count":19},"Respiratory Effort",{"name":27,"count":19},"Sleep Apnea, Obstructive",{"name":29,"count":30},"Tuberculosis",1,{"name":32,"count":30},"Withdrawal Syndrome",[34,39,43],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06983886","The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery","2026-06-30","Tranexamic Acid",{"nctId":40,"briefTitle":41,"date":37,"intervention":42},"NCT06965088","Comparison of Recurrence Rate of Keloid After Excision Between Intra-operative Steroid Injection and Steroid With Platelet-rich Plasma Injection Combination Therapy","Combined Intra-operative platelet-rich plasma with corticosteroid",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06453603","Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome","2026-12-31","PRP",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,82,100,118,141,159,183,201,227,245,270,295,324,342,367,394,412,430,457,475,501,526,551,578,596,622,640,666,684,710,736,754,772,809,832,857,875,900,926,944,968,986,1010],{"intervention":38,"totalTrials":30,"cells":57},{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":76,"PHASE4":78,"NA":80},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":30,"soonestReadout":37},[65],{"nctId":35,"briefTitle":36,"status":66,"phases":67,"primaryCompletion":37,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":73},"NOT_YET_RECRUITING",[50,51],"2026-09-30","2025-05-12",25,[72],"Postoperative Blood Loss in Patient Undergoing Orthognathic Surgery",[38,74,75],"Normal Saline Solution","Lidocaine",{"trials":77,"activeCount":60},[],{"trials":79,"activeCount":60},[],{"trials":81,"activeCount":60},[],{"intervention":74,"totalTrials":30,"cells":83},{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":94,"PHASE4":96,"NA":98},{"trials":85,"activeCount":60},[],{"trials":87,"activeCount":60},[],{"trials":89,"activeCount":30,"soonestReadout":37},[90],{"nctId":35,"briefTitle":36,"status":66,"phases":91,"primaryCompletion":37,"completion":68,"start":69,"enrollment":70,"conditions":92,"interventions":93},[50,51],[72],[38,74,75],{"trials":95,"activeCount":60},[],{"trials":97,"activeCount":60},[],{"trials":99,"activeCount":60},[],{"intervention":75,"totalTrials":30,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":112,"PHASE4":114,"NA":116},{"trials":103,"activeCount":60},[],{"trials":105,"activeCount":60},[],{"trials":107,"activeCount":30,"soonestReadout":37},[108],{"nctId":35,"briefTitle":36,"status":66,"phases":109,"primaryCompletion":37,"completion":68,"start":69,"enrollment":70,"conditions":110,"interventions":111},[50,51],[72],[38,74,75],{"trials":113,"activeCount":60},[],{"trials":115,"activeCount":60},[],{"trials":117,"activeCount":60},[],{"intervention":42,"totalTrials":30,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":135,"PHASE4":137,"NA":139},{"trials":121,"activeCount":60},[],{"trials":123,"activeCount":60},[],{"trials":125,"activeCount":30,"soonestReadout":37},[126],{"nctId":40,"briefTitle":41,"status":127,"phases":128,"primaryCompletion":37,"completion":68,"start":129,"enrollment":130,"conditions":131,"interventions":133},"ACTIVE_NOT_RECRUITING",[51],"2025-04-28",212,[132],"Patients With Keloid Scar",[42,134],"Intra-operative corticosteroid",{"trials":136,"activeCount":60},[],{"trials":138,"activeCount":60},[],{"trials":140,"activeCount":60},[],{"intervention":134,"totalTrials":30,"cells":142},{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":153,"PHASE4":155,"NA":157},{"trials":144,"activeCount":60},[],{"trials":146,"activeCount":60},[],{"trials":148,"activeCount":30,"soonestReadout":37},[149],{"nctId":40,"briefTitle":41,"status":127,"phases":150,"primaryCompletion":37,"completion":68,"start":129,"enrollment":130,"conditions":151,"interventions":152},[51],[132],[42,134],{"trials":154,"activeCount":60},[],{"trials":156,"activeCount":60},[],{"trials":158,"activeCount":60},[],{"intervention":47,"totalTrials":30,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":162,"activeCount":60},[],{"trials":164,"activeCount":60},[],{"trials":166,"activeCount":60},[],{"trials":168,"activeCount":60},[],{"trials":170,"activeCount":60},[],{"trials":172,"activeCount":30,"soonestReadout":46},[173],{"nctId":44,"briefTitle":45,"status":66,"phases":174,"primaryCompletion":46,"completion":46,"start":175,"enrollment":176,"conditions":177,"interventions":181},[54],"2024-07-01",24,[178,179,180],"Pes Anserine Bursitis","Steroid Injection","PRP Injection",[47,182],"corticosteroid",{"intervention":182,"totalTrials":30,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":186,"activeCount":60},[],{"trials":188,"activeCount":60},[],{"trials":190,"activeCount":60},[],{"trials":192,"activeCount":60},[],{"trials":194,"activeCount":60},[],{"trials":196,"activeCount":30,"soonestReadout":46},[197],{"nctId":44,"briefTitle":45,"status":66,"phases":198,"primaryCompletion":46,"completion":46,"start":175,"enrollment":176,"conditions":199,"interventions":200},[54],[178,179,180],[47,182],{"intervention":202,"totalTrials":30,"cells":203},"40 mg Triamcinolone acetate 1 cc",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":225},{"trials":205,"activeCount":60},[],{"trials":207,"activeCount":60},[],{"trials":209,"activeCount":60},[],{"trials":211,"activeCount":60},[],{"trials":213,"activeCount":60},[214],{"nctId":215,"briefTitle":216,"status":217,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT03273036","Perioperative Outcome of Corticosteroids in Transforaminal Endoscopic Lumbar Discectomy","COMPLETED",[53],"2015-05-01","2014-05-01",30,[21],[202,224],"Placebos",{"trials":226,"activeCount":60},[],{"intervention":224,"totalTrials":30,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":243},{"trials":230,"activeCount":60},[],{"trials":232,"activeCount":60},[],{"trials":234,"activeCount":60},[],{"trials":236,"activeCount":60},[],{"trials":238,"activeCount":60},[239],{"nctId":215,"briefTitle":216,"status":217,"phases":240,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":241,"interventions":242},[53],[21],[202,224],{"trials":244,"activeCount":60},[],{"intervention":246,"totalTrials":30,"cells":247},"pitavastatin",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":268},{"trials":249,"activeCount":60},[],{"trials":251,"activeCount":60},[],{"trials":253,"activeCount":60},[],{"trials":255,"activeCount":60},[],{"trials":257,"activeCount":60},[258],{"nctId":259,"briefTitle":260,"status":217,"phases":261,"primaryCompletion":262,"completion":262,"start":263,"enrollment":176,"conditions":264,"interventions":267},"NCT02442700","Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir\u002FRitonavir",[53],"2015-01","2014-05",[265,266],"HIV","Dyslipidemia",[246],{"trials":269,"activeCount":60},[],{"intervention":271,"totalTrials":30,"cells":272},"Simethicone",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":293},{"trials":274,"activeCount":60},[],{"trials":276,"activeCount":60},[],{"trials":278,"activeCount":60},[],{"trials":280,"activeCount":60},[],{"trials":282,"activeCount":60},[283],{"nctId":284,"briefTitle":285,"status":217,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT00615303","The Effectiveness of Simethicone In Improving Visibility During Colonoscopy",[53],"2007-12","2006-12",194,[291],"Colonoscopy",[271],{"trials":294,"activeCount":60},[],{"intervention":296,"totalTrials":30,"cells":297},"Rosuvastatin",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":322},{"trials":299,"activeCount":60},[],{"trials":301,"activeCount":60},[],{"trials":303,"activeCount":60},[],{"trials":305,"activeCount":60},[],{"trials":307,"activeCount":60},[308],{"nctId":309,"briefTitle":310,"status":311,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":320},"NCT00866229","Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level","UNKNOWN",[53],"2010-03","2010-06","2008-04",140,[318,319],"Systemic Lupus Erythematosus","High LDL Cholesterol Level",[296,321],"Simvastatin",{"trials":323,"activeCount":60},[],{"intervention":321,"totalTrials":30,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":340},{"trials":327,"activeCount":60},[],{"trials":329,"activeCount":60},[],{"trials":331,"activeCount":60},[],{"trials":333,"activeCount":60},[],{"trials":335,"activeCount":60},[336],{"nctId":309,"briefTitle":310,"status":311,"phases":337,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":338,"interventions":339},[53],[318,319],[296,321],{"trials":341,"activeCount":60},[],{"intervention":343,"totalTrials":30,"cells":344},"Dexlansoprazole 60 mg once daily",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":365},{"trials":346,"activeCount":60},[],{"trials":348,"activeCount":60},[],{"trials":350,"activeCount":60},[],{"trials":352,"activeCount":60},[],{"trials":354,"activeCount":60},[355],{"nctId":356,"briefTitle":357,"status":217,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":364},"NCT03087162","Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori",[53],"2017-12-01","2017-01-01",180,[363],"H Pylori Eradication",[343],{"trials":366,"activeCount":60},[],{"intervention":368,"totalTrials":30,"cells":369},"Lidocaine 3 cc",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":392},{"trials":371,"activeCount":60},[],{"trials":373,"activeCount":60},[],{"trials":375,"activeCount":60},[],{"trials":377,"activeCount":60},[],{"trials":379,"activeCount":60},[380],{"nctId":381,"briefTitle":382,"status":217,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":389},"NCT03120923","Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome",[53],"2016-08-01","2015-01-01",52,[388],"Impingement Shoulder",[368,390,391],"Lidocaine 9 cc","Triamcinolone Acetonide",{"trials":393,"activeCount":60},[],{"intervention":390,"totalTrials":30,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":410},{"trials":397,"activeCount":60},[],{"trials":399,"activeCount":60},[],{"trials":401,"activeCount":60},[],{"trials":403,"activeCount":60},[],{"trials":405,"activeCount":60},[406],{"nctId":381,"briefTitle":382,"status":217,"phases":407,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":408,"interventions":409},[53],[388],[368,390,391],{"trials":411,"activeCount":60},[],{"intervention":391,"totalTrials":30,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":428},{"trials":415,"activeCount":60},[],{"trials":417,"activeCount":60},[],{"trials":419,"activeCount":60},[],{"trials":421,"activeCount":60},[],{"trials":423,"activeCount":60},[424],{"nctId":381,"briefTitle":382,"status":217,"phases":425,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":426,"interventions":427},[53],[388],[368,390,391],{"trials":429,"activeCount":60},[],{"intervention":431,"totalTrials":30,"cells":432},"Glucosamine sulfate",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":455},{"trials":434,"activeCount":60},[],{"trials":436,"activeCount":60},[],{"trials":438,"activeCount":60},[],{"trials":440,"activeCount":60},[],{"trials":442,"activeCount":60},[443],{"nctId":444,"briefTitle":445,"status":217,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":454},"NCT01906801","Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine",[53],"2014-10","2013-07",148,[451,452,453],"Osteoarthritis","Glucosamine","Diacerein",[431,453],{"trials":456,"activeCount":60},[],{"intervention":453,"totalTrials":30,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":473},{"trials":460,"activeCount":60},[],{"trials":462,"activeCount":60},[],{"trials":464,"activeCount":60},[],{"trials":466,"activeCount":60},[],{"trials":468,"activeCount":60},[469],{"nctId":444,"briefTitle":445,"status":217,"phases":470,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":471,"interventions":472},[53],[451,452,453],[431,453],{"trials":474,"activeCount":60},[],{"intervention":476,"totalTrials":30,"cells":477},"Goserelin",{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":484,"PHASE4":486,"NA":499},{"trials":479,"activeCount":60},[],{"trials":481,"activeCount":60},[],{"trials":483,"activeCount":60},[],{"trials":485,"activeCount":60},[],{"trials":487,"activeCount":60},[488],{"nctId":489,"briefTitle":490,"status":217,"phases":491,"primaryCompletion":492,"completion":493,"start":315,"enrollment":494,"conditions":495,"interventions":498},"NCT00851461","Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy",[53],"2011-11","2013-11",10,[496,497],"Spinobulbar Muscular Atrophy","Kennedy's Disease",[476],{"trials":500,"activeCount":60},[],{"intervention":502,"totalTrials":30,"cells":503},"Dextran 40",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":522,"NA":524},{"trials":505,"activeCount":60},[],{"trials":507,"activeCount":60},[],{"trials":509,"activeCount":60},[],{"trials":511,"activeCount":60},[512],{"nctId":513,"briefTitle":514,"status":217,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":494,"conditions":518,"interventions":521},"NCT03070353","Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury",[51,52],"2016-06-30","2015-07-01",[519,520],"Cirrhosis, Liver","AKI",[502],{"trials":523,"activeCount":60},[],{"trials":525,"activeCount":60},[],{"intervention":527,"totalTrials":30,"cells":528},"fluticasone propionate",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":547,"NA":549},{"trials":530,"activeCount":60},[],{"trials":532,"activeCount":60},[],{"trials":534,"activeCount":60},[],{"trials":536,"activeCount":60},[537],{"nctId":538,"briefTitle":539,"status":217,"phases":540,"primaryCompletion":541,"completion":542,"start":262,"enrollment":543,"conditions":544,"interventions":546},"NCT02523820","Nebulized Corticosteroid for Post Extubation Stridor in Children",[52],"2016-05-30","2016-08-30",144,[545],"Stridor",[527],{"trials":548,"activeCount":60},[],{"trials":550,"activeCount":60},[],{"intervention":552,"totalTrials":30,"cells":553},"Methylene Blue",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":574,"NA":576},{"trials":555,"activeCount":60},[],{"trials":557,"activeCount":60},[],{"trials":559,"activeCount":60},[],{"trials":561,"activeCount":60},[562],{"nctId":563,"briefTitle":564,"status":311,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":572},"NCT03038503","What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin",[52],"2018-12","2016-12",60,[570,571],"Septic Shock","Refractory Shock",[552,573],"Terlipressin",{"trials":575,"activeCount":60},[],{"trials":577,"activeCount":60},[],{"intervention":573,"totalTrials":30,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":592,"NA":594},{"trials":581,"activeCount":60},[],{"trials":583,"activeCount":60},[],{"trials":585,"activeCount":60},[],{"trials":587,"activeCount":60},[588],{"nctId":563,"briefTitle":564,"status":311,"phases":589,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":590,"interventions":591},[52],[570,571],[552,573],{"trials":593,"activeCount":60},[],{"trials":595,"activeCount":60},[],{"intervention":597,"totalTrials":30,"cells":598},"Ringer acetate",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":618,"NA":620},{"trials":600,"activeCount":60},[],{"trials":602,"activeCount":60},[],{"trials":604,"activeCount":60},[],{"trials":606,"activeCount":60},[607],{"nctId":608,"briefTitle":609,"status":217,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":568,"conditions":613,"interventions":616},"NCT02336620","Balanced Salt Solution VS. Normal Saline Solution in Septic Shock",[52],"2017-01-30","2014-12",[614,615],"Shock, Septic","Sepsis",[597,617],"Normal saline",{"trials":619,"activeCount":60},[],{"trials":621,"activeCount":60},[],{"intervention":617,"totalTrials":30,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":636,"NA":638},{"trials":625,"activeCount":60},[],{"trials":627,"activeCount":60},[],{"trials":629,"activeCount":60},[],{"trials":631,"activeCount":60},[632],{"nctId":608,"briefTitle":609,"status":217,"phases":633,"primaryCompletion":611,"completion":611,"start":612,"enrollment":568,"conditions":634,"interventions":635},[52],[614,615],[597,617],{"trials":637,"activeCount":60},[],{"trials":639,"activeCount":60},[],{"intervention":641,"totalTrials":30,"cells":642},"oral alfacalcidol",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":644,"activeCount":60},[],{"trials":646,"activeCount":60},[],{"trials":648,"activeCount":60},[649],{"nctId":650,"briefTitle":651,"status":311,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT01364688","Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease",[51],"2012-11","2012-12","2011-05",80,[15],[641,659],"no drug",{"trials":661,"activeCount":60},[],{"trials":663,"activeCount":60},[],{"trials":665,"activeCount":60},[],{"intervention":659,"totalTrials":30,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":669,"activeCount":60},[],{"trials":671,"activeCount":60},[],{"trials":673,"activeCount":60},[674],{"nctId":650,"briefTitle":651,"status":311,"phases":675,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":676,"interventions":677},[51],[15],[641,659],{"trials":679,"activeCount":60},[],{"trials":681,"activeCount":60},[],{"trials":683,"activeCount":60},[],{"intervention":685,"totalTrials":30,"cells":686},"25% intravenous (IV) sodium thiosulfate",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":688,"activeCount":60},[],{"trials":690,"activeCount":60},[],{"trials":692,"activeCount":60},[693],{"nctId":694,"briefTitle":695,"status":217,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT00720772","Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis",[51],"2009-05","2009-11","2008-07",50,[702,15],"Coronary Calcification",[685],{"trials":705,"activeCount":60},[],{"trials":707,"activeCount":60},[],{"trials":709,"activeCount":60},[],{"intervention":711,"totalTrials":30,"cells":712},"fentanyl, propofol, atracurium",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":714,"activeCount":60},[],{"trials":716,"activeCount":60},[],{"trials":718,"activeCount":60},[719],{"nctId":720,"briefTitle":721,"status":217,"phases":722,"primaryCompletion":723,"start":724,"enrollment":568,"conditions":725,"interventions":727},"NCT02065947","Three-level Injection Paravertebral Block vs General Anesthesia in Mastectomy",[50,51],"2014-03","2013-10",[726],"Radical Mastectomy",[711,728,729],"lidocaine , adrenaline, ketamine bolus, midazolam","sevoflurane and 50% oxygen in air",{"trials":731,"activeCount":60},[],{"trials":733,"activeCount":60},[],{"trials":735,"activeCount":60},[],{"intervention":728,"totalTrials":30,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":739,"activeCount":60},[],{"trials":741,"activeCount":60},[],{"trials":743,"activeCount":60},[744],{"nctId":720,"briefTitle":721,"status":217,"phases":745,"primaryCompletion":723,"start":724,"enrollment":568,"conditions":746,"interventions":747},[50,51],[726],[711,728,729],{"trials":749,"activeCount":60},[],{"trials":751,"activeCount":60},[],{"trials":753,"activeCount":60},[],{"intervention":729,"totalTrials":30,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":757,"activeCount":60},[],{"trials":759,"activeCount":60},[],{"trials":761,"activeCount":60},[762],{"nctId":720,"briefTitle":721,"status":217,"phases":763,"primaryCompletion":723,"start":724,"enrollment":568,"conditions":764,"interventions":765},[50,51],[726],[711,728,729],{"trials":767,"activeCount":60},[],{"trials":769,"activeCount":60},[],{"trials":771,"activeCount":60},[],{"intervention":773,"totalTrials":19,"cells":774},"NSS",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":776,"activeCount":60},[],{"trials":778,"activeCount":60},[],{"trials":780,"activeCount":60},[],{"trials":782,"activeCount":60},[],{"trials":784,"activeCount":60},[],{"trials":786,"activeCount":60},[787,798],{"nctId":788,"briefTitle":789,"status":217,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":796},"NCT02950974","Change in Serum Chloride Level After Loading Dose of Sterofundin Solution Compared With Normal Saline Solution",[54],"2015-03","2014-11",20,[795],"Change in Serum Chloride Level",[797,773],"Sterofundin",{"nctId":799,"briefTitle":800,"status":217,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":807},"NCT02948920","Single Bolus Intravenous Ephedrine Attenuates Reduction of Core Body Temperature in Patients Undergoing Spinal Anesthesia for Arthroscopic Knee and Ankle Surgery",[54],"2017-07-27","2016-09-22",40,[806],"Body Temperature Changes",[808,773],"Ephedrine",{"intervention":810,"totalTrials":30,"cells":811},"silymarin",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":813,"activeCount":60},[],{"trials":815,"activeCount":60},[],{"trials":817,"activeCount":60},[],{"trials":819,"activeCount":60},[],{"trials":821,"activeCount":60},[],{"trials":823,"activeCount":60},[824],{"nctId":825,"briefTitle":826,"status":217,"phases":827,"primaryCompletion":828,"completion":448,"start":829,"enrollment":656,"conditions":830,"interventions":831},"NCT01800487","The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs",[54],"2013-06","2012-01",[29],[810],{"intervention":833,"totalTrials":30,"cells":834},"Thiamine",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":836,"activeCount":60},[],{"trials":838,"activeCount":60},[],{"trials":840,"activeCount":60},[],{"trials":842,"activeCount":60},[],{"trials":844,"activeCount":60},[],{"trials":846,"activeCount":60},[847],{"nctId":848,"briefTitle":849,"status":217,"phases":850,"primaryCompletion":851,"completion":851,"start":852,"enrollment":853,"conditions":854,"interventions":856},"NCT02767245","Thiamine Supplement in Patients With Severe Hyperthyroidism",[54],"2016-07","2014-01",12,[855],"Thyrotoxicosis",[833],{"intervention":797,"totalTrials":30,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":860,"activeCount":60},[],{"trials":862,"activeCount":60},[],{"trials":864,"activeCount":60},[],{"trials":866,"activeCount":60},[],{"trials":868,"activeCount":60},[],{"trials":870,"activeCount":60},[871],{"nctId":788,"briefTitle":789,"status":217,"phases":872,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":873,"interventions":874},[54],[795],[797,773],{"intervention":876,"totalTrials":30,"cells":877},"Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":879,"activeCount":60},[],{"trials":881,"activeCount":60},[],{"trials":883,"activeCount":60},[],{"trials":885,"activeCount":60},[],{"trials":887,"activeCount":60},[],{"trials":889,"activeCount":60},[890],{"nctId":891,"briefTitle":892,"status":217,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT01580865","Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis",[54],"2017-03","2012-05",84,[898],"Lupus Nephritis",[876],{"intervention":901,"totalTrials":30,"cells":902},"Fluorometholone",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":904,"activeCount":60},[],{"trials":906,"activeCount":60},[],{"trials":908,"activeCount":60},[],{"trials":910,"activeCount":60},[],{"trials":912,"activeCount":60},[],{"trials":914,"activeCount":60},[915],{"nctId":916,"briefTitle":917,"status":217,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":656,"conditions":922,"interventions":924},"NCT01288404","Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium",[54],"2010-09","2010-11","2008-01",[923],"Pterygium of the Conjunctiva and Cornea",[901,925,925,925],"Bevacizumab",{"intervention":925,"totalTrials":30,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":929,"activeCount":60},[],{"trials":931,"activeCount":60},[],{"trials":933,"activeCount":60},[],{"trials":935,"activeCount":60},[],{"trials":937,"activeCount":60},[],{"trials":939,"activeCount":60},[940],{"nctId":916,"briefTitle":917,"status":217,"phases":941,"primaryCompletion":919,"completion":920,"start":921,"enrollment":656,"conditions":942,"interventions":943},[54],[923],[901,925,925,925],{"intervention":945,"totalTrials":30,"cells":946},"Metformin+Enalapril+Simvastatin",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":948,"activeCount":60},[],{"trials":950,"activeCount":60},[],{"trials":952,"activeCount":60},[],{"trials":954,"activeCount":60},[],{"trials":956,"activeCount":60},[],{"trials":958,"activeCount":60},[959],{"nctId":960,"briefTitle":961,"status":311,"phases":962,"primaryCompletion":851,"completion":567,"start":829,"enrollment":963,"conditions":964,"interventions":967},"NCT01364675","Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects",[54],8900,[965,966],"Pre-diabetes","Pre-hypertension",[945],{"intervention":808,"totalTrials":30,"cells":969},{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":971,"activeCount":60},[],{"trials":973,"activeCount":60},[],{"trials":975,"activeCount":60},[],{"trials":977,"activeCount":60},[],{"trials":979,"activeCount":60},[],{"trials":981,"activeCount":60},[982],{"nctId":799,"briefTitle":800,"status":217,"phases":983,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":984,"interventions":985},[54],[806],[808,773],{"intervention":987,"totalTrials":30,"cells":988},"0.18% sodium hyaluronate",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":990,"activeCount":60},[],{"trials":992,"activeCount":60},[],{"trials":994,"activeCount":60},[],{"trials":996,"activeCount":60},[],{"trials":998,"activeCount":60},[],{"trials":1000,"activeCount":60},[1001],{"nctId":1002,"briefTitle":1003,"status":217,"phases":1004,"primaryCompletion":314,"completion":919,"start":1005,"enrollment":700,"conditions":1006,"interventions":1008},"NCT01363414","Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes",[54],"2007-01",[1007],"Dry Eye",[987,1009],"0.9% sodium chloride solution",{"intervention":1009,"totalTrials":30,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1013,"activeCount":60},[],{"trials":1015,"activeCount":60},[],{"trials":1017,"activeCount":60},[],{"trials":1019,"activeCount":60},[],{"trials":1021,"activeCount":60},[],{"trials":1023,"activeCount":60},[1024],{"nctId":1002,"briefTitle":1003,"status":217,"phases":1025,"primaryCompletion":314,"completion":919,"start":1005,"enrollment":700,"conditions":1026,"interventions":1027},[54],[1007],[987,1009]]